Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 16,102 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Withdrawn Phase 3 Interventional

Nitropaste in Breast Reduction

NCT04321967
View directory record Official record
Conditions
Gynecomastia, Delayed Wound Healing
Interventions
Nitroglycerin Paste, Dermabond
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Phase 2 Interventional

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

NCT05137067
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo, Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Dietary Supplement · Drug
Lead sponsor
Optimal Health Research
Other
Eligibility
25 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 25, 2026, 6:53 AM EDT
Completed No phase listed Observational Results available

A Clinical Investigation of the Discovery™ Elbow System

NCT00698867
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis, Humeral Fractures
Interventions
Not listed
Lead sponsor
Biomet Orthopedics, LLC
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
4
States / cities
Tampa, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

NCT00279734
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tetanus + pnemococcal vaccines alone, Abatacept + Vaccines
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Lenexa, Kansas • Baltimore, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 25, 2026, 6:53 AM EDT
Completed No phase listed Observational

PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial

NCT00940199
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 25, 2026, 6:53 AM EDT
Active, not recruiting Not applicable Interventional Results available

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

NCT03075072
View directory record Official record
Conditions
Brain Metastases
Interventions
Whole brain radiation, Stereotactic radiation (SRS)
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a New Dressing for Use With Topical Medications

NCT00234728
View directory record Official record
Conditions
Psoriasis
Interventions
Occlusive dressing
Device
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 25, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

Tolerability of 532 nm Laser Treatment of Port Wine Stains

NCT05841628
View directory record Official record
Conditions
Port-Wine Stain
Interventions
532 nm laser treatment
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 25, 2026, 6:53 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

NCT01849328
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Rauscher, Gregory E., M.D. PA
Individual
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 25, 2026, 6:53 AM EDT
Not yet recruiting Phase 2 Interventional

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

NCT07619365
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Lovastatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

NCT00609011
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
MPC-6827 + Temozolomide
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Ocoee, Florida • Greenville, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 25, 2026, 6:53 AM EDT
Terminated No phase listed Observational Results available

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

NCT03709771
View directory record Official record
Conditions
Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions
Ambulatory Blood Pressure Measurement
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Phase 1 Interventional

Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC)

NCT06006299
View directory record Official record
Conditions
Breast Cancer, Insomnia
Interventions
transauricular Vagus Nerve Stimulation
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer

NCT01931163
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Everolimus
Drug
Lead sponsor
Jenny C. Chang, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

NCT00730028
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Trimethoprim-sulfamethoxazole, Placebo, Clindamycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 85 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
San Francisco, California • Torrance, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 25, 2026, 6:53 AM EDT
Completed No phase listed Observational

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

NCT04035811
View directory record Official record
Conditions
Achondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 17 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
QGE031, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 25, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Jacksonville, Florida • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 6:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Histamine Pharmacogenetics in Children With Atopic Dermatitis

NCT00277433
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Buccal Swab
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Months to 5 Years
Enrollment
751 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 25, 2026, 6:53 AM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

NCT04166552
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Patients will be randomized to receive EHP-101 or Placebo
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Gamma Vacuum Foil (GVF) Versus Cross-linked Polyethylene in Total Knee Arthroplasty Study

NCT00289133
View directory record Official record
Conditions
Osteoarthritis, Knee, Arthritis, Rheumatoid
Interventions
total knee arthroplasty
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
Up to 80 Years
Enrollment
938 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
9
States / cities
Mobile, Alabama • Berkley, California • Fort Collins, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 25, 2026, 6:53 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

NCT05157958
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
ALLO-ASC-SHEET, Vehicle Control
Biological · Other
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
4 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 25, 2026, 6:53 AM EDT
Completed Phase 1 Interventional

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911
View directory record Official record
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 25, 2026, 6:53 AM EDT